Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

@inproceedings{Butov2011PhaseIR,
  title={Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB},
  author={Dmitry A. Butov and Yuri N Pashkov and Anna L. Stepanenko and Aleksandra I Choporova and Tanya S Butova and Dendev Batdelger and Vichai Jirathitikal and Aldar S. Bourinbaiar and Svetlana I Zaitzeva},
  booktitle={Journal of immune based therapies and vaccines},
  year={2011}
}
Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases to investigate the safety and efficacy of an oral immune adjunct (V5). The immunotherapy (N = 24) and placebo (N = 10) arms received once-daily tablet of V5 or placebo for one month in addition to conventional anti-TB therapy (ATT) administered under directly observed therapy (DOT).The enlarged liver, total bilirubin, erythrocyte… CONTINUE READING
Highly Cited
This paper has 154 citations. REVIEW CITATIONS
6 Citations
41 References
Similar Papers

Citations

Publications citing this paper.

155 Citations

050100150'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 155 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis

  • OV Arjanova, ND Prihoda, +5 authors AS Bourinbaiar
  • J Vaccin Vaccinat
  • 2010
3 Excerpts

Role of adjunctive Mycobacterium w immunotherapy for tuberculosis

  • PS Nyasulu
  • J Exp Clin Med
  • 2010

Ruti

  • J Stanford, C Stanford, J Grange
  • 2010

Similar Papers

Loading similar papers…